| Cancer Information Highlights | | From the National Cancer Institute | | Updating you about cancer causes, prevention, screening, treatment, coping, and more | | | | New from NCI | | NCI Annual Plan & Budget Proposal for Fiscal Year 2023 |  | | Each year, NCI prepares a plan for advancing cancer research and proposes the budget required to fund a broad research portfolio, support the cancer research workforce, and sustain the infrastructure that makes progress against cancer possible. | | Physical Activity May Lessen the Effects of Chemobrain |  | | For people getting chemotherapy for breast cancer, meeting the national physical activity guidelines may help ease cognitive issues. The benefits may be even greater for people who were active before starting treatment. | Opioid Use Drops among People with Cancer at the End of Life
A new study shows that people with cancer at the end of their lives may not be getting opioids to control their pain. Filled prescriptions for opioids dropped among these people during the study period, and ER visits for cancer pain went up dramatically. | Belumosudil Approved to Treat Chronic Graft-Versus-Host Disease
People with chronic graft-versus-host disease (GVHD), a common complication of bone marrow and stem cell transplants, now have a new treatment option. The Food and Drug Administration (FDA) has approved belumosudil (Rezurock) for people 12 years and older who have already tried at least two other therapies for the disease. | | A Diverse Workforce with a Shared Mission |  | | Meet members of the cancer research workforce who are working together across scientific fields, guiding the next generation of diverse and talented scientists, and driving progress against cancer. | Photodynamic Therapy for Cancer
This updated page explains photodynamic therapy. Learn what photodynamic therapy is, how it works, the types of cancer and precancers that it is used to treat, and the benefits and drawbacks of this treatment.
| | FDA Approvals | Nivolumab
We've updated our nivolumab (Opdivo) drug summary with a new FDA approval. Nivolumab is now approved for use after surgery to remove urothelial cancer in people whose cancer has a high risk of coming back. | | | | | Also of Interest | Coronavirus: What People with Cancer Should Know
Learn how to protect yourself from COVID-19 and find advice on extra vaccine shots for people with weakened immune systems. | Contact Us for Help
Information specialists at NCI's Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email. | | | | | |
No comments:
Post a Comment